|

Metastatic Breast Cancer in Austria

RECRUITINGSponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie
Actively Recruiting
SponsorArbeitsgemeinschaft medikamentoese Tumortherapie
Started2015-06-15
Est. completion2025-06
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

Breast cancer is the most common cancer among women worldwide. In Austria, this diagnosis is made more than 5000 times a year (STATISTICS AUSTRIA, Austrian Cancer Registry, as of 24.09.2012). Of these, already 5% to 10% have distant metastases at the time of initial diagnosis, and up to 30% of the node-negative tumours and up to 70% of the node-positive tumours metastasise at a later date. Metastatic breast cancer has not been systematically assessed in Austria to date. This medical registry of the AGMT is thus the first Austrian-wide standardised documentation of this disease. The aim of the registry is to answer both epidemiological and therapy-specific questions. This registry is a prospective and retrospective, multicentre collection of data on patients with metastatic breast cancer in Austria. All tumour characteristics, medical histories and also treatment sequences are documented in anonymised form.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Histological evidence of breast cancer
* Histological and/or radiological evidence of metastases
* Metastasis within 10 years of registry initiation
* Signed informed consent (if a patient has already died at the time of entry, the entry can be made without a declaration of consent)

Exclusion Criteria:

* Due to the non-interventional design of the registry there are no specific exclusion criteria.

Conditions4

Breast CancerBreast CarcinomaBreast TumorCancer

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.